A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review

For advanced lung adenocarcinoma patients with common epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or the exon 21 L858R mutation), tyrosine kinase inhibitors (TKIs) are the standard therapies, and achieve favorable responses. However, for the rare EGFR deletion-insertion muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yu, Cui, Yueli, Guo, Yao, Li, Lei, Zeng, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226096/
https://www.ncbi.nlm.nih.gov/pubmed/34178699
http://dx.doi.org/10.3389/fonc.2021.700345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226096/
https://www.ncbi.nlm.nih.gov/pubmed/34178699
http://dx.doi.org/10.3389/fonc.2021.700345

Ejemplares similares